Safety Trial of 68Ga/177Lu-NRT6020 in FAP-Positive Advanced Solid Tumor Patients

NCT06911489 · clinicaltrials.gov ↗

PHASE1

Phase

RECRUITING

Status

132

Enrollment

INDUSTRY

Sponsor class

Conditions

Solid Tumor Malignancy

Interventions

DIAGNOSTIC_TEST: 68Ga-NRT6020 Injection
DRUG: 177Lu-NRT6020 Injection (stage 2)
DRUG: 177Lu-NRT6020 Injection (stage 3)

Sponsor

Chengdu New Radiomedicine Technology Co. LTD.